Greenwich Choral Society Unveils First Virtual Performance

GREENWICH, CT — The Greenwich Choral Society announced Tuesday its first virtual performance is now available for viewing.

In light of the coronavirus, the society has suspended group rehearsals and public concerts and “embarked on a program of recording virtual performances” to be shared virtually with the public, according to a release. (To sign up for Greenwich breaking news alerts and more, click here.)

Their first performance, James E. Moore’s arrangement of “An Irish Blessing,” is available for viewing through the society’s website.

For their first performance, choristers recorded their vocal parts in their homes. These separate parts were then sent in and combined through a computer program to create a full performance.

The society has also opened its weekly Zoom online rehearsals to any in the community who would like to find out more about creating choral music at this time. No auditions are required to participate, just an

Read More

Sapreme Unveils its Proprietary Endosomal Escape Platform in Presentations at 16th Annual Meeting of Oligonucleotide Therapeutics Society

 

Sapreme, a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, today announced positive preclinical data on its proprietary endosomal escape platform in two presentations at the 16th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), held virtually from September 27th to 30th, 2020.

Sapreme is developing macromolecule delivery methods based on compounds that release therapeutic cargo from the endo-lysosome, improving access to intracellular targets and enhancing the therapeutic window for these therapeutics. Current macromolecular biologics rely on receptor-mediated endocytic uptake into the endosome and inefficient passive release from these vesicles into the cell to achieve therapeutic efficacy. The company’s presentations demonstrate that Sapreme’s SPT001 compound improves intracellular release of targeted antisense oligonucleotides (ASOs) and thereby also their therapeutic efficacy. In addition to ASOs, SPT001 has also been demonstrated to enhance delivery of other targeted payloads such as antibody-conjugated toxins.

“The data presented today

Read More